



# HCV NS5B Mutations

HCV genotype 1a		
CODON	Dasabuvir 1a	Sofosbuvir 1a
S282T		R 3, 7, 9
C316Y	R 1, 2, 4, 5, 8	
L320F		R 7
A395G	R 1	
M414I	R 4, 5, 8	
M414T	R 1, 2, 4, 5, 8	
N444K	R 1	
E446K	R 4, 5	
E446Q	R 4, 5	
Y448C	R 1, 4, 5	
Y448H	R 1, 2, 4, 5	
A553T	R 2, 4, 5, 8	
G554S	R 2, 4, 5, 8	
S556F	R 1	
S556G	R 1, 2, 4, 5, 8	
S556R	R 2, 4, 5	
Y561H	R 2, 4, 5	
S565F	R 1	

HCV genotype 1b		
CODON	Dasabuvir 1b	Sofosbuvir 1b
L159F+L320F		R 7
V179A		R 3
S282T		R 3, 7, 9, 10
C316H	R 4, 5	
C316N	R 1, 2, 4, 5	
C316Y	R 1, 2, 4, 5	S 3
S368T	R 1, 4, 5	
N411S	R 1, 4, 5	
M414I	R 4, 5	
M414T	R 1, 2, 4, 5	S 3
Y448C	R 1, 4, 5	
Y448H	R 2, 4, 5	
C451S	R 1	
A553V	R 1, 4, 5	
S556G	R 1, 2, 4, 5	
D559G	R 4, 5	

HCV genotype 2		
CODON	Dasabuvir 2	Sofosbuvir 2
282T		R 3, 10
289L		R 3

HCV genotype 3		
CODON	Dasabuvir 3	Sofosbuvir 3
S282T		R 6, 10

## REFERENCES

1. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. *Antimicrob Agents Chemother.*, 59(3):1505-11, 2015
2. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/003837/WC500182233.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf)
3. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. *Antimicrob Agents Chemother.*, 56(6):3359-68, 2012
4. PI Viekira XR HCV NS5B resistance.
5. PI Viekira Pak HCV NS5B resistance.
6. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 2015. *Hepatology*. Nov; Hepatitis C virus drug resistance-associated substitutions: State of the art summary.
7. Tong X1, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I. 2014. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. *JID*. Mar 1;209(5):668-75.
8. Krishnan P, Tripathi R, Schnell G, et al. Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir. *AAC* Sept 2015, Vol 59, 9. 5445.
9. Harvoni PI Revised 02/2017.
10. Epclusa PI revised 06/2016.